Influence of i diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation

Nuclear Medicine Communications

Volumn 25, Issue 8, 2004, Pages 793-797

  Hu, Ya Hui ^a   Wang, Pei Wen ^a   Wang, Shan Tair ^a   Lee, Chiang Hsuan ^b   Chen, Hue Yong ^b   Chou, Fong Fu ^b   Huang, Yu Erh ^b   Huang, Hsu Hua ^b  

^a Chang Gung Memorial Hospital   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Radioiodine ablation; Thyroid cancer; Thyroid stunning

Indexed keywords

IODINE 131; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; RADIATION DOSE; SCINTIGRAPHY; STATISTICAL ANALYSIS; THYROID CARCINOMA; THYROIDECTOMY; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; EPIDEMIOLOGY; METHODOLOGY; PROGNOSIS; RADIATION EXPOSURE; RADIATION INJURY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; TAIWAN; THYROID GLAND; THYROID TUMOR; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; CAUSALITY; COMORBIDITY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; PROGNOSIS; RADIATION DOSAGE; RADIATION INJURIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TAIWAN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 4143092509     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000126626.17166.ed     Document Type: Article

References (13)

1. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13:277-279.
2. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4:49-54.
3. 131I. Nucl Med Commun 1996; 17:839-842.
4. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18:505-512.
5. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevaher A, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242-246.
6. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1546-1550.
7. Yeung HWD, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 2000; 41:1082-1085.
8. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185-MBq I-131. J Nucl Med 2000; 41:1198-1202.
9. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86:3507-3511.
10. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499-1501.
11. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-428.
12. Rawson RW, Rall JE, Peacock W. Limitation and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol 1951; 11:1128-1142.
13. Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by I-131 irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43:828-834.